Search Results - "Scheithauer W"

VEGF and EGFR inhibition: opening a new door to cancer treatment.

Alternate Title: VEGF-Hemmer und EGFR-Inhibitoren: neue Wege in der Krebsbehandlung.

Authors: Scheithauer, W. Pirker, R. Grünberger, T. et al.

Source: European Surgery: ACA Acta Chirurgica Austriaca. Feb2010, Vol. 42 Issue 1, p24-28. 5p. 1 Diagram, 2 Charts, 2 Graphs.

Phase II trial of gemcitabine, epirubicin and granulocyte colony-stimulating factor in patients with advanced pancreatic adenocarcinoma.

Authors: Scheithauer, W Kornek, G V Raderer, M et al.

Source: British Journal of Cancer. 8/1/99, Vol. 80 Issue 11, p1797. 6p.

Capecitabine versus 5-fluorouracil/folinic acid as adjuvant therapy for stage III colon cancer: final results from the X-ACT trial with analysis by age and preliminary evidence of a pharmacodynamic marker of efficacy.

Authors: Twelves, C. Scheithauer, W. McKendrick, J. et al.

Source: Annals of Oncology. May2012, Vol. 23 Issue 5, p1190-1197. 8p. 2 Diagrams, 4 Charts, 2 Graphs.

Original article The role of oxaliplatin in the management of upper gastrointestinal tract malignancies.

Authors: Scheithauer, W. Van Cutsemt, E.

Source: Colorectal Disease. Nov2003 Supplement 3, Vol. 5, p36-44. 9p.

Absence of Therapeutic Efficacy of the Somatostatin Analogue Lanreotide in Advanced Primary Hepatic Cholangiocellular Cancer and Adenocarcinoma of the Gallbladder Despite In Vivo SomatostatinReceptor Expression.

Authors: Fiebiger, W. C. C. Scheithauer, W. Traub, T. et al.

Source: Scandinavian Journal of Gastroenterology. Feb2002, Vol. 37 Issue 2, p222-225. 4p. 2 Black and White Photographs.

K-ras mutations and cetuximab in colorectal cancer.

Authors: Winder T Scheithauer W Lang A

Source: New England Journal of Medicine. 2/19/2009, Vol. 360 Issue 8, p834-836. 3p.

Current treatment benefits in advanced colorectal cancer.

Authors: Scheithauer W (AUTHOR)

Source: Lancet Oncology. Oct2007, Vol. 8 Issue 10, p857-859. 3p.

HER 2/neu protein expression in colorectal cancer.

Authors: Schuell, B Gruenberger, T Scheithauer, W et al.

Source: BMC Cancer. 2006, Vol. 6, p123-5. 5p. 2 Charts, 1 Graph.

3O LONG-TERM MAINTENANCE THERAPY WITH THE TLR-9 AGONIST MGN1703 IN A SUBGROUP OF METASTATIC COLORECTAL CANCER PATIENTS FROM THE IMPACT STUDY.

Authors: Scheithauer, W. Riera-Knorrenschild, J. Kopp, H. et al.

Source: Annals of Oncology. Nov2014, Vol. 25 Issue suppl_6, pvi1-vi2. 1p.

253 INVITED Tailored Adjuvant Chemotherapy According to Pathological Response (?)

Authors: Scheithauer, W.

Source: European Journal of Cancer. Sep2011 Supplement 1, Vol. 47, pS59-S60. 0p.

Importance of response to neoadjuvant chemotherapy in potentially curable colorectal cancer liver metastases.

Authors: Gruenberger B Scheithauer W Punzengruber R et al.

Source: BMC Cancer. 2008, Vol. 8, p120-120. 1p.

Preoperative sequential short-term radiotherapy plus chemotherapy can induce complete remission on T3N2 rectal cancer.

Authors: Widder J Herbst F Scheithauer W

Source: Acta Oncologica. Dec2005, Vol. 44 Issue 8, p921-923. 3p.

URL: 19063569

XELOX vs FOLFOX-4 as first-line therapy for metastatic colorectal cancer: NO16966 updated results.

Authors: Cassidy, J. Clarke, S. D&a#x00ED;az-Rubio, E. et al.

Source: British Journal of Cancer. 6/20/2011, Vol. 105 Issue 1, p58-64. 7p. 1 Diagram, 4 Charts, 1 Graph.

Estimating prognosis and palliation based on tumour marker CA 19-9 and quality of life indicators in patients with advanced pancreatic cancer receiving chemotherapy.

Authors: Bernhard, J. Dietrich, D. Glimelius, B. et al.

Source: British Journal of Cancer. 10/26/2010, Vol. 103 Issue 9, p1318-1324. 7p. 3 Charts, 3 Graphs.

Gemcitabine and oxaliplatin in advanced biliary tract carcinoma: a phase II study.

Authors: André, T. Reyes-Vidal, J. M. Fartoux, L. et al.

Source: British Journal of Cancer. 9/16/2008, Vol. 99 Issue 6, p862-867. 6p. 3 Charts, 2 Graphs.

Pharmacoeconomic analysis of adjuvant oral capecitabine vs intravenous 5-FU/LV in Dukes' C colon cancer: the X-ACT trial.

Authors: Cassidy, J. Douillard, J.-Y. Twelves, C. et al.

Source: British Journal of Cancer. 4/24/2006, Vol. 94 Issue 8, p1122-1129. 8p. 5 Charts, 3 Graphs.

Side effects during chemotherapy predict tumour response in advanced colorectal cancer.

Authors: Schuell, B. Gruenberger, T. Kornek, G. V. et al.

Source: British Journal of Cancer. 10/3/2005, Vol. 93 Issue 7, p744-748. 5p.

Irinotecan plus raltitrexed vs raltitrexed alone in patients with gemcitabine-pretreated advanced pancreatic adenocarcinoma.

Authors: Ulrich-Pur, H. Raderer, M. Kornek, G.V. et al.

Source: British Journal of Cancer. 4/22/2003, Vol. 88 Issue 8, p1180-1184. 5p.

Effective combination chemotherapy with paclitaxel and cisplatin with or without human granulocyte colony-stimulating factor and/or erythropoietin in patients with advanced gastric cancer.

Authors: Kornek, G.V. Raderer, M. Schull, B. et al.

Source: British Journal of Cancer. 6/17/2002, Vol. 86 Issue 12, p1858-1863. 6p.

Treatment of unresectable, locally advanced pancreatic adenocarcinoma with combined radiochemotherapy with 5-fluorouracil, leucovorin and cisplatin.

Authors: Kornek, G V Schratter-Sehn, A Marczell, A et al.

Source: British Journal of Cancer. 1/1/2000, Vol. 82 Issue 1, p98. 6p.